The reporter learned from Chengdu High tech Zone in Sichuan Province that the "WGc-043 Injection" independently developed by Chengdu Weisjin Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as "Weisjin Biotechnology") has been approved by the Drug Evaluation Center of the China National Medical Products Administration to conduct Phase I clinical trials after obtaining clinical trial approval from the US Food and Drug Administration in May this year. According to Song Congrong, co-founder and general manager of Wistron Biotech, the EB virus has been identified as a Group 1 carcinogen by the International Agency for Research on Cancer and is the first human tumor causing virus discovered. EB virus is highly associated with more than 10 types of malignant tumors, including nasopharyngeal carcinoma, lymphoma, and gastric cancer. And mRNA tumor therapeutic vaccines are currently one of the major breakthroughs in the field of mRNA innovative drugs and tumor immunotherapy. WGc-043 Injection is an mRNA vaccine for the treatment of EB virus positive tumors. Currently, the vaccine has completed clinical trials initiated by researchers for two indications: nasopharyngeal carcinoma and natural killer T-cell lymphoma Song Congrong said that the vaccine is expected to provide new treatment options for patients with end-stage nasopharyngeal carcinoma and natural killer T-cell lymphoma. The approval of this new drug clinical trial reflects our maturity in mRNA core technologies such as delivery vectors and sequence design Next, we will conduct multicenter clinical trials in China to promote the rapid launch of the WGc-043 mRNA vaccine, "said Song Congrong